28 July 2020: Original Paper
Effect of Concentration/Dose Ratio in Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial
Barbara Suwelack 1ABDE* , Suphamai Bunnapradist 2BDE , Ulf Meier-Kriesche 3ACDE , Daniel R. Stevens 3ACDE , Claudio Procaccianti 4ACDE , Roberto Morganti 4ACDE , Klemens Budde 5ACDEDOI: 10.12659/AOT.923278
Ann Transplant 2020; 25:e923278
Figure 6 Clinical outcomes overall and by metabolizer phenotype. The analysis population consisted of patients who had a calculable day 30 C/D ratio based on central or local laboratory data. For all patients and within metabolizer subgroups, there were no statistically significant differences between treatments for any event. BKV, BK viremia; BKVN – BK virus nephropathy; BPAR – biopsy-proven acute rejection; CMV – cytomegalovirus; DGF – delayed graft function.